JP2025512709A5 - - Google Patents
Info
- Publication number
- JP2025512709A5 JP2025512709A5 JP2024553306A JP2024553306A JP2025512709A5 JP 2025512709 A5 JP2025512709 A5 JP 2025512709A5 JP 2024553306 A JP2024553306 A JP 2024553306A JP 2024553306 A JP2024553306 A JP 2024553306A JP 2025512709 A5 JP2025512709 A5 JP 2025512709A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- expression vector
- seq
- pharmaceutical composition
- shrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263317154P | 2022-03-07 | 2022-03-07 | |
| US63/317,154 | 2022-03-07 | ||
| PCT/US2023/014679 WO2023172534A2 (en) | 2022-03-07 | 2023-03-07 | shRNA TARGETING UBE3A-ATS TO RESTORE PATERNAL UBE3A GENE EXPRESSION IN ANGELMAN SYNDROME |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025512709A JP2025512709A (ja) | 2025-04-22 |
| JP2025512709A5 true JP2025512709A5 (enExample) | 2026-03-16 |
Family
ID=87935840
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024553306A Pending JP2025512709A (ja) | 2022-03-07 | 2023-03-07 | アンジェルマン症候群における父方由来ＵＢＥ３Ａ遺伝子発現を回復させるためのＵＢＥ３Ａ－ＡＴＳを標的とするｓｈＲＮＡ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230332157A1 (enExample) |
| EP (1) | EP4473114A2 (enExample) |
| JP (1) | JP2025512709A (enExample) |
| KR (1) | KR20240154664A (enExample) |
| CN (1) | CN119053703A (enExample) |
| AU (1) | AU2023232014A1 (enExample) |
| CA (1) | CA3254296A1 (enExample) |
| IL (1) | IL315364A (enExample) |
| MX (1) | MX2024010821A (enExample) |
| WO (1) | WO2023172534A2 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025101991A1 (en) * | 2023-11-09 | 2025-05-15 | Ionis Pharmaceuticals, Inc. | Methods for modulating ube3a-ats |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8058516B2 (en) * | 2000-07-19 | 2011-11-15 | Monsanto Technology Llc | Rice metallothionein promoters |
| WO2017083722A1 (en) * | 2015-11-11 | 2017-05-18 | Greenberg Kenneth P | Crispr compositions and methods of using the same for gene therapy |
| EP4143581A1 (en) * | 2020-04-27 | 2023-03-08 | Biogen MA Inc. | Methods of detecting ube3a protein |
-
2023
- 2023-03-07 KR KR1020247033383A patent/KR20240154664A/ko active Pending
- 2023-03-07 WO PCT/US2023/014679 patent/WO2023172534A2/en not_active Ceased
- 2023-03-07 IL IL315364A patent/IL315364A/en unknown
- 2023-03-07 AU AU2023232014A patent/AU2023232014A1/en active Pending
- 2023-03-07 EP EP23767379.3A patent/EP4473114A2/en active Pending
- 2023-03-07 CA CA3254296A patent/CA3254296A1/en active Pending
- 2023-03-07 CN CN202380026099.XA patent/CN119053703A/zh active Pending
- 2023-03-07 US US18/179,726 patent/US20230332157A1/en active Pending
- 2023-03-07 JP JP2024553306A patent/JP2025512709A/ja active Pending
-
2024
- 2024-09-04 MX MX2024010821A patent/MX2024010821A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022518504A5 (enExample) | ||
| IL278213B1 (en) | A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd) | |
| JP2024045131A (ja) | 神経変性疾患の遺伝子治療 | |
| JP2022513456A5 (enExample) | ||
| CA3165624A1 (en) | Gene therapy for neurodegenerative disorders using polynucleotide silencing and replacement | |
| CN102227500A (zh) | 胆色素原脱氨酶基因治疗 | |
| RS63942B1 (sr) | Proizvodi i postupci za lečenje amiotrofične lateralne skleroze | |
| JP2022505381A5 (enExample) | ||
| JP2020054367A (ja) | 改変ｇ６ｐｃをコードするアデノ随伴ウイルスベクターおよびその使用 | |
| JP2023501897A5 (enExample) | ||
| JP2023534037A5 (enExample) | ||
| JP2024508696A5 (enExample) | ||
| JP2023542211A5 (enExample) | ||
| WO2020142714A1 (en) | Aav expression cassette and aav vectors comprising the same | |
| EP4069263A1 (en) | Transgene cassettes designed to express a human mecp2 gene | |
| JP2023500793A5 (enExample) | ||
| WO2024006741A1 (en) | Aav capsid variants and uses thereof | |
| JP2022553573A5 (enExample) | ||
| JP2022501044A5 (enExample) | ||
| JP2023553005A (ja) | 末梢ミエリンタンパク質２２の発現の阻害のための生成物及び方法 | |
| JP2024523445A5 (enExample) | ||
| JP2021534794A5 (enExample) | ||
| JP2025512709A5 (enExample) | ||
| JP2025509262A5 (enExample) | ||
| EP4627093A1 (en) | Adeno-associated viral vectors for proper packaging of repetitive elements |